Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
1.560
-0.080 (-4.88%)
At close: Feb 21, 2025, 4:00 PM
1.610
+0.050 (3.21%)
After-hours: Feb 21, 2025, 6:27 PM EST
Outlook Therapeutics Stock Forecast
OTLK's stock price has decreased by -82.02% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Outlook Therapeutics stock have an average target of 12, with a low estimate of 3.00 and a high estimate of 33. The average target predicts an increase of 669.23% from the current stock price of 1.56.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Outlook Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 5 | 5 | 4 |
| Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $30 → $3 | Strong Buy | Maintains | $30 → $3 | +92.31% | Feb 18, 2025 |
| Chardan Capital | Chardan Capital | Hold Maintains $3 | Hold | Maintains | $3 | +92.31% | Feb 18, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +669.23% | Jan 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +1,823.08% | Jan 17, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Dec 2, 2024 |
Financial Forecast
Revenue This Year
10.14M
Revenue Next Year
50.37M
from 10.14M
Increased by 396.84%
EPS This Year
-2.28
from -4.06
EPS Next Year
-0.80
from -2.28
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 16.8M | 53.5M | 156.9M | ||
| Avg | 10.1M | 50.4M | 128.2M | ||
| Low | 3.9M | 47.0M | 95.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 427.7% | 211.4% | ||
| Avg | - | 396.8% | 154.6% | ||
| Low | - | 364.0% | 90.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.31 | -0.43 | 1.32 | ||
| Avg | -2.28 | -0.80 | 1.14 | ||
| Low | -3.19 | -1.14 | 0.90 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.